I'm just teasing.
Good morning. My name is Bill Plovanic. I'm a Senior Medical Device Analyst here at Canaccord. With us next is TriSalus, and we're going to have a fireside chat with the management team. With us today, we have Mary Szela, CEO and President, and we have David Patience, CFO. Thank you for joining.
Yeah.
Thank you for having us.
Thanks for having us.
All right. Let's kick it off, and we'll dig right in with numbers because we're finance people. That's what we have to do. Just on guidance, it's the second guidance reset this year. Sorry, I have to start off on a negative tone here, but we're now at $46 million-$48 million versus we were much higher, $54 million-$57 million previously. What went differently than you expected with the new territory ramp, and what do you think will change in the future that builds the new range you're guiding to?
Do you want to start, David?
Sure.
I can jump in.
Yeah. With us, as a reminder, we expanded the sales organization back in the first half of the year, and with that, it's about 1/3 of the field is new, and that expansion is taking, as you noted, a little bit longer than we anticipated. For us, we were anticipating a six to nine-month ramp. It's taking probably closer to 9 to 12. We're seeing strong sequential growth in that cohort over the second quarter, third quarter, and into the fourth quarter. The historical territories have also been performing in line with expectations, and so we think we have the right formula. It's just taking a little bit longer. With that, we were just overly optimistic with that expansion cohort, and we've reflected in our guide for the fourth quarter kind of where they are and the anticipated growth in the fourth quarter.
Yeah. I think where we misjudged is these expansion territories were really new. We hadn't been in those markets in a big way previously, so it just took a little bit longer for reps to get in the door with the physician, spend some time with them, get acclimated before they got off and running. We're just seeing that delayed by about a quarter.
As we think of the reps you hired, was the kind of makeup or qualities or skills different in any way than your current kind of sales force, or did you go beyond, or is it all kind of the same type of rep?
No, I think with the raise, we were really able to get a different caliber of rep. These are people who really knew the interventional radiology environment. This is all just them getting new and acclimation to the product. I was really pleased with the level of talent and a lot of people coming to the company just because they saw the growth opportunities. So frankly, we got a lot of really good people that we're thrilled about.
Back to guidance, the new range for Q4 is basically flat to up $2 million sequentially, which is typically the strongest quarter. Is there a headwind or anything that's causing you concern, or is this, as we like to say, is this just pure conservatism given you had to reset, you're like, "Okay, that's
I think we set our range for the fourth quarter in a very prudent way given what has happened this year. We want to ensure that we are meeting expectations and have upside from those expectations.
Yeah. We set a guide that we couldn't miss.
That I like to hear. On the TriNav Advance here in limited launch, how much of that's baked into the fourth quarter?
None.
None.
None. All right. You said that the new cohort of reps, every month they're seeing improvement.
Yeah.
I think in the call you said September was a record.
Yeah. Yep.
Can we assume that October and November are records?
Yes.
Well, November's not done yet.
Yeah, we don't give any forward guidance.
Yeah.
But yeah, no, we're really happy with where they are and the momentum that they're building.
Okay. You've said that 2027 growth should be very meaningful double-digit growth rates. How do we frame the building blocks between maturing reps, TriNav Advance, then we will get into OBL reimbursement? How do we frame those three kind of ingredients, and then what is your going to be your approach to the 2027 OPPS guide? Then lastly, I noticed only us and somebody else updated numbers for this 2027 at this point. I think I am 59. They are about 56.
Yeah.
How do you feel about those numbers at this point?
You want to start? There were a lot of questions in that one single question.
Yeah, I know. I'm sorry.
You're going to have to keep us honest on that.
Yeah. The way we think about kind of the building blocks for next year, like you said, is a full year of the expanded commercial organization with those expansion territories really being fully productive for probably three-quarters of the year. That is the most material driver of our growth next year in our core business in the liver. We're very excited again with the progress that they're making. Launching TriNav Advance will also be of an ability for us to engage interventional radiologists to get those super selective cases that we're missing today to expand wallet share within those accounts, to improve same store sales, but also introduce Pressure-Enabled Drug Delivery to folks that are not using our technology today. It also will be a big catalyst for new accounts.
Additionally, in the reimbursement, we also don't want to overlook that we did see a change in our simulation or mapping for Y-90 cases that brought that mapping procedure before you have the radiation dose to the procedural reimbursement rate of over $20,000. We think that will also be a catalyst kind of in our core business today. With the G- code, we have great reimbursement that gives us access to a new site of care, which we also think will be a great growth lever for us. We don't want to really get into framing that from a fiscal standpoint just yet. It's a little too early. The G- code is brand new to us, so we want to provide more guidance on the Q4 call.
Well, and I'd imagine you're going through your 2027 budgeting process right now.
Right.
[uncertain], if you were a CFO. I'm going to switch back to sales force productivity. Actually, you didn't answer the question of, we're at $59 million.
Yes.
Yeah.
Another one to $56 million. How do you
I think that's an appropriate range for where we are right now. The timing and the magnitude of these growth levers we're very excited about, but it's a little too early to commit to those.
Yeah.
Okay. You are still in process.
Yeah.
Sales force productivity. How are the existing reps and territories producing relative to the plan? This is more the existing.
Because you split some of their territories.
Right.
I do not know if you moved anybody into new territories or if it is just
We did. I mean, we did all of the above, and we kind of look at three different separate groups. But our reps that came into kind of previous territories or established territories, they've performed really well. We're really pleased with their performance. It was really these newly created territories where we put a new rep in. We had not had business previously. Those are the ones that took longer.
Okay. For the, I think it was an interesting nuance, and I picked up on the call, but you have eight new territories you talked about. It's about a third of the field, below plan. Where specifically is it the gap? Is it in getting the account open? Is it time to first case? Is it utilization once they're open? Like, where is it kind of slower?
I'd say it was time to first case. It just took a little bit longer.
They're getting the accounts.
They're getting into the accounts, but part of what we always ask our reps to do is get into the procedural room with the physician, get to know his practice. We're going to highlight TriNav where it has its biggest benefit. How do you get them to use the first case and convince them clinically this makes sense? That just took a little longer because they were new. These physicians never had been really called on for TriNav before, so it took longer.
They're getting the openings, they're getting [crosstalk].
Oh, yeah. [crosstalk].
Through the VACs, they're getting through all that. Just getting to first case [crosstalk]
Yeah [crosstalk].
Use and the momentum.
Yeah.
Okay. You've noted no rep turnover and continued growth in ordering accounts and units. How do we think about that? Because I think one of the biggest issues we run into when we see challenges, companies that expand their sales forces significantly, within 12 months, 20%, 30% of all new rep hires maybe walk out the door. It wasn't the right person, wasn't the right experience level, or what have you. How do you feel about kind of that? What are you seeing in the hires? I think you said you haven't had turnover yet, but what do you kind of If you look at the ones that are underperforming, because sometimes then they're like, "Oh, I'm not making enough money here.
Right. Or they don't feel the growth opportunities, or this is a lot harder than I thought it was, and all of those reasons before. I think we were very specific about the phenotype of the individual that we hired, and I think that helped a lot. So, reps knew they could be very successful here. We also laid out a whole platform of growth drivers over multiple years. We have a very attractive compensation plan. A lot of the reps came together kind of in clumps of people that all worked together in another company that really were high performers, so that gave us a lot of confidence about they came as a group and kind of spread across the country.
So, I think there's a lot of excitement in the organization right now. There's always going to be turnover in an organization, but it won't certainly be like the disruption that we had this year.
All right. Sales and marketing was running at roughly $11 million a quarter. You have expanded the sales force. Is the current footprint the right size through 2027, or do you think you are going to be consolidating some underperforming territories, and what do you think the normal sales and marketing spend is going forward?
Maybe I can take that. When we were going through this process, we had a pretty high level of confidence that we were able to get the reimbursement in the G- code. When we looked at the footprint, it was not only for the hospital market, it was also for the OBL market. We wanted to have the same rep have a smaller territory and cover all of that. Having done that in the past with different reps, that creates a lot of just challenge in terms of managing. We built the footprint for where we were going. This footprint is one that we think we do not need incremental reps for quite some time.
Does going into the OBL require a different skill set for the sales rep or?
No.
No.
You know, it is really [crosstalk].
Site of care is irrelevant.
Yeah, what's really interesting now is, a lot of hospitals, big academic centers, just because when a patient goes into the hospital, the IR has a lot of other responsibilities in addition to his case, so they get pulled apart and patients wait for a long time. We're seeing OBLs set up around these big academic centers, so doctors move pretty fluidly between these two. Even the ones that are privately owned, they move fluidly between hospitals. We want reps in a geography where they know those physicians and cover both sides. Really, the procedure is essentially the same. Regardless of the site.
Yeah. In the final 2027 OPPS, the mapping moves to APC, you got higher reimbursement, same as embolization procedures. How does that change the hospital economics, and could it increase TriNav use in mapping in units per patient?
Absolutely. I mean, one of the challenges we had with mapping, we've been promoting concordance, where you want to use the same technology for simulation. You can see the vascular anatomy, you can calculate the dose, and use the same technology and treatment. Where we were challenged is the reimbursement was lower for mapping, so oftentimes they were confused about, "Well, what should I use? I really want to use TriNav in the hospital, but I can't map with it if I do it in the OBL." So now we've basically made that the same. What we argued to CMS is the work was the same, so it should be the same compensation, and they agreed.
Given the OBL reimbursement, I think one of the questions I asked you last night was, the docs, if now they're doing this in their office and they have higher reimbursement, why wouldn't they use the standard end-hole catheter, get the money, and pocket it? Sorry, versus-
Well, we really, obviously what we wanted to do is when we spoke to CMS, and the reason why I think they supported this is, this is a big cost difference versus the hospital, so it's a cost savings to CMS, number one, because the overhead is much lower. It's much better for the patient because then you can schedule the procedures. They don't get suspended waiting for four hours where the IR has to do something else. They wanted to make it economically attractive to the physician because they viewed that migration out of the hospital into the OBL as something very favorable to them.
All right. I'm going to flip to TriNav Advance. We are a little confused on this. You called out super selective [crosstalk].
Yep.
Of Y-90 as a headwind this quarter. What percentage of your sales is that today? What percentage of the market is it? How big of a shift in the practice is this? It is kind of like you have the solution with TriNav Advance, but you have this thing going on.
Yeah, so maybe to be clear about it is super selective or using, having IRs go down to singular vessels and delivering the radiation to the tumor has been growing in adoption. It is only feasible for about 20% of the market. It is smaller tumors. Because you see such favorable responses when they do it, they have been trying to go a little bit above that, and that is what we saw in terms of the trend. You need a very tiny catheter size. We did not have that. Advance now addresses that. So that opens up that whole market that we were not in before.
That is the wallet share that we are able to capture now with Advance.
Yeah. So it is 20% of the market today.
Around there.
As you have it. Yeah. Of the radiation.
Incremental for you.
Yes, that's incremental.
Just for the audience, if we have any newcomers to the story, explain the difference between your standard TriNav and the Advance product.
Today, if a standard TriNav is a catheter and it has a tiny valve on the end. Because it has that little valve on the end, when an interventional radiologist is tracking to a site, it feels a little different because it's got that valve on the end, so the trackability and the pushability feels different. There's a number of physicians who are like, "Hey, I grew up on my microcatheter. I've been doing this for 10 or 15 years. I know the type of results I get. I don't really care about what you're saying. This is what I know, and this is what I do well. I want to use the same microcatheter." So, we developed a system where they could still get that Pressure-Enabled Drug Delivery benefit with the valve, and they put their own standard microcatheter through our guide catheter with the valve.
We're just still early in the pilot phase, but we're getting really favorable feedback on it because it does a couple things. Number one, even in that small tumor, the visibility of the vascularity is markedly different, number one. Number two, they're giving a much higher dose of radiation. The market's migrated from like 100 gray in the tumor to 400 gray, so substantially higher. They want to get an ablative dose. Now they're more concerned about off-target delivery, so having TriNav prevents off-target delivery. With that valve and the stability of the Advance catheter, their microcatheter even becomes more trackable, and they can do it faster. Then they can also get more drug into the tumor.
So, we're really excited about this option for them. So, it addresses the physician that never wanted to move to TriNav. It addresses super selective, so it does a couple different things.
How should we think about Advance pricing, coding, and gross margin relative to the core TriNav?
It's the same. Every product in our portfolio is comparable gross margin, comparable price. So, it really makes no difference what the physician uses.
It's incremental even if it's cannibalizing itself.
Doesn't matter.
It doesn't. It's irrelevant.
It's relevant.
Okay. The final rule language around PEDD is broader than before on the reimbursement side. Does that open the door to competition? And how do you protect the franchise through IP and clinical data?
Right. So, in that, if you read through the OPPS ruling, we actually had some conversations with the CMS about that, and we continue to. We won't comment any further on that.
All right. I won't push you on it.
On the clinical evidence, you've got 11 active studies across 27 sites. You got a lot going on.
We do.
We got a couple of readouts in 2027. Just high level, what's the most important things that investors should focus on, and what's it going to do for you?
We have a couple new studies at the end of the year. We had the feeder study that's really going to talk about more tumor, more dose to tumor, and less to normal tissue. It's a comparative study that we think this will be a really nice catalyst. In the first quarter, we'll have data emerging from the first ever thyroid embolization with PEDD in over 100 patients, where we'll have outcome data on that. We think that could position us. We're already included in some thyroid guidelines. We think this could be another data set that potentially could go into a broader endocrine guidelines, and also spur much more further options for academic centers to set up their own thyroid program.
We're kicking off our, we call this a foundational study, where we're actually comparing TriNav to the end-hole catheter with outcome data, with the goal that we get it in the NCCN Guidelines. Then we have numerous different, I won't go through all the different studies that we have, but numerous ones throughout 2027. Part of our goal is, how do we create the clinical evidence for physicians to adopt this readily? How do we remove any of the economic barriers that a hospital or a physician may encounter? And how do we support them commercially so they can drive adoption in their patient populations?
How much of the use of the product today is liver or thyroid?
The majority. Majority of that, yeah.
Okay.
About only a small percentage right now is uterine fibroid. However, in the OBL, that's the dominant procedure in the OBL, prostate and uterine fibroid.
Switching to nelitolimod, the readout's still expected [crosstalk].
Yep.
By year end?
Yep.
You have said the pancreatic landscape has changed. What would the data need to show to justify further investment, and is partnering still the most likely?
Yes, we plan to release that data in December. I think that will be the catalyst for us to really start the partnering discussions. I think on the pancreatic environment, we're trying to think through, it is changing really rapidly, especially with Revolution Medicines and their recent launch and how fast it's moving into first line. We're going to need to shoot ahead of the duck. We don't know how long chemo will really be first line, so we're trying to think through. There's about 20 different companies with RAS inhibitors right now. We're trying to pick the combination that we may want to partner with on the pancreatic side.
Well, we're Canadian here, so it's ahead of the puck.
Yep. That is right. I forgot about that.
You ended the third quarter with $41 million in cash, used about $5 million in operations. What revenue level do you expect to reach cash flow break-even? Especially because the numbers changed, right?
Yep.
Can you get there without additional capital?
Yeah. We think we can. We are not going to give guidance on break-even today, but we will bring more clarity to the street closer to probably the fourth quarter call and during the fourth quarter call. We are really excited about those growth levers. I think we want to show and prove that we can see those out with the really strong and durable gross margins we have, and what we think will be a very stable cost structure. We think we are well on our way in moving our EBITDA loss from $7 million to about $4.5 million-$5 million last quarter was great, tremendous progress, and we want to continue to show that to the street.
Excellent. Let us see if there is any other questions for the audience. Nope. Crickets.
Well, thank you.
Yeah. Thank you.
Thank you.
Thank you.
Really appreciate it.
Thank you so much.